Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia (WM): Real‑world evidence from the United States
This retrospective observational study evaluated real‑world treatment utilization, sequencing patterns, and healthcare resource utilization (HCRU) among patients with Waldenström macroglobulinemia (WM) in the United States.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Waldenström Macroglobulinemia Clinical Trials
- Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?